Inspire Medical CFO Rick Buchholz to Step Down at Year’s End

Inspire Medical Systems, a company specializing in minimally invasive solutions for obstructive sleep apnea (OSA), revealed that Chief Financial Officer (CFO) Rick Buchholz will step down from his position at the company on December 31, 2025 to pursue other professional opportunities.

Buchholz will stay employed with the company in a financial advisory role through February 28, 2026 to ensure a smooth transition. The company has begun an active search to identify its next CFO.

“Since joining Inspire in 2014, Rick has provided steady leadership and invaluable guidance, leaving a lasting impact on the company,” said Tim Herbert, Chairman and CEO, Inspire Medical Systems. “He played a pivotal role in our journey—from the commercial launch, where revenue grew from $4 million to over $800 million in 2024, through our initial public offering, the challenges of the COVID-19 pandemic, and ultimately to becoming a profitable enterprise. On a personal note, I want to thank Rick for his unwavering dedication and partnership over the years.”

“It has been a great honor to be a part of the Inspire journey,” said Buchholz. “As I move on to my next endeavors, I am committed to ensuring a smooth transition to help the company find the financial leader for the next phase of growth.”

The company reaffirmed its previously issued guidance for full-year 2025 with revenue guidance of $900 to $910 million, gross margin guidance of 84% to 86% and diluted net income per share guidance of $0.40 to $0.50.

Inspire received U.S. Food and Drug Administration (FDA) clearance for its Inspire V therapy system to treat OSA in August 2024.